Bayer Announces Senior Bayer Representative and President of Bayer U.S.

Sebastian Guth appointed to lead Bayer’s U.S. operations

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country’s leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S.

Sebastian Guth, Bayer’s President of Pharmaceuticals Americas, assumes this leadership role, which oversees all Bayer U.S. operations, on June 30, 2023.

Guth, who has been with Bayer for 17 years, will retain leadership of the Pharmaceuticals business for the U.S., a critical growth market for the company, and Canada. Bayer will shift oversight of the company’s Latin America Pharmaceuticals business to Heike Prinz, Head of Commercial Operations for the EMEA Pharmaceuticals business.

“I am honored to lead Bayer U.S.,” said Sebastian Guth, incoming Senior Bayer Representative and President of Bayer U.S. and Pharmaceuticals North America. “I look forward to working with the country leadership team and the entire organization in this new capacity as we continue to accelerate growth and foster an inclusive, vibrant, and entrepreneurial culture in the U.S. I am excited about our future.”

An inventive and inspirational leader, Guth has played an instrumental role in driving growth and innovation. Most recently as President of Bayer’s Pharmaceuticals business for the Americas region, he has led the successful turnaround of the U.S. business, reigniting the company’s growth momentum and expanding its commercial footprint. Guth’s leadership has delivered results in both strategic and operational roles at the most senior levels in a variety of settings and cultures. Prior to his current role, he served as Executive Vice President and Chief Marketing Officer for Bayer's global Pharmaceuticals business. Previously, Guth served as President & Chief Executive Officer of Bayer Yakuhin Ltd., Osaka, leading Bayer's healthcare business in Japan.

“Sebastian Guth is a seasoned leader who has successfully guided the North America Pharmaceuticals business to growth, with a focus on strategy and innovation that has benefitted countless patients and helped strengthen Bayer,” said Wolfgang Nickl, CFO and Member of the Board of Management at Bayer. “His experience and deep understanding of the business, customers and other stakeholders will benefit our entire U.S. organization and help advance Bayer’s global success.”

Guth started his career in the pharmaceuticals industry with Schering AG, where he held senior roles in Asia, Europe and the Middle East. Following Bayer's acquisition of Schering in 2006, Sebastian served as Chief Executive Officer of Bayer Turk, Istanbul, and was Senior Representative of the Bayer Group in Turkey.

A strong advocate for workplace culture, including advancing diversity, equity & inclusion, Guth currently serves as Bayer’s Executive Sponsor for GROW, the company’s business resource group focused on advocating for women’s advancement. He also works with partners across the pharmaceuticals industry through his role as a Board Member of the Pharmaceutical Research and Manufacturers of America (PhRMA), chairing its FDA and Biomedical Research Committee. He is a member of the Health Section Governing Board of BIO and is a Trustee of Children’s Aid, one of America’s oldest and largest child welfare organizations.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Social Media Channels

- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.